Skip to main content
Equibles
FENC logo

FENC · Fennec Pharmaceuticals Inc.

Track FENC — free

Use FENC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about FENC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$11.72 -0.34 (-2.82%) At close · Aug 14
Market Cap
$410.99M
Shares
35.07M

Fennec Pharmaceuticals Inc. Earnings Call Transcripts

Every quarterly earnings call for Fennec Pharmaceuticals Inc. (FENC) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $1.68M −$6.05M '23 Q1 23-05-11 · $3.33M −$5.44M '23 Q2 23-08-04 · $6.51M −$1.87M '23 Q3 23-11-07 · $9.73M −$2.68M '23 Q4 24-03-21 ▲1413.2% $25.38M $12.84M '24 Q1 24-05-14 ▲118.4% $7.26M −$5.55M '24 Q2 24-08-13 ▲7% $6.97M −$5.74M '24 Q3 24-11-07 ▼18.6% $7.92M −$1.99M '24 Q4 25-03-10 ▼65.5% $8.75M −$1.17M '25 Q1 25-05-13 ▲32.9% $9.65M −$3.15M '25 Q2 25-08-14 ▲73.8% $13.78M −$4.79M '25 Q4 26-03-24 ▲72.6% $15.11M $201,000 '26 Q1 26-05-14 LATEST ▲85.2% $17.87M $1.97M '26 Q2 26-08-11
Earnings call
FY26 · Q2
2026-08-11
Fennec Pharmaceuticals Q2 2026 Conference Call
Confident tone Pedmark clinical adoption in AYA / adult cisplatin patients Project Ignite / commercial field force expansion Market access / GPO and EMR integration
Revenue
$17.87M
▲ 85.2% YoY
Diluted EPS
$0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-19
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-19
H.C. WAINWRIGHT 4TH ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-14
FENNEC PHARMACEUTICALS Q1 2026 CONFERENCE CALL
Confident tone PEDMARK label expansion and clinical evidence Pipeline expansion into new tumor types Commercial execution and field force expansion
Revenue
$15.11M
▲ 72.6% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Fennec Pharmaceuticals Inc. Q4 FY2025 Earnings Call
Confident tone AYA and Indication Expansion Commercial Growth and Sales Execution Sales Force Expansion
Revenue
$13.78M*
▲ 73.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-08-14
Fennec Pharmaceuticals Inc. Q2 FY2025 Earnings Call
Confident tone Revenue Growth and Commercial Performance PEDMARK Adoption and Standard of Care International Expansion via Norgine
Revenue
$9.65M
▲ 32.9% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Fennec Pharmaceuticals Inc. Q1 FY2025 Earnings Call
Confident tone AYA (adolescent and young adult) market expansion European launch via Norgine partnership (PEDMARQSI) Fennec HEARS patient support program
Revenue
$8.75M
▼ 65.5% YoY
Diluted EPS
$-0.04
▼ 109.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Fennec Pharmaceuticals Inc. Q4 FY2024 Earnings Call
Confident tone AYA market expansion European launch via Norgine NCCN compendia and guidelines
Revenue
$7.92M*
▼ 18.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Fennec Pharmaceuticals Inc. Q3 FY2024 Earnings Call
Confident tone PEDMARK commercial execution and five strategic pillars AYA (Adolescent and Young Adult) market expansion Pediatric and academic center adoption vs. compounding
Revenue
$6.97M
▲ 7% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Fennec Pharmaceuticals Inc. Q2 FY2024 Earnings Call
Confident tone PEDMARK commercial launch Norgine partnership (PEDMARQSI ex-U.S.) Leadership transition / new CEO
Revenue
$7.26M
▲ 118.4% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Fennec Pharmaceuticals Inc. Q1 FY2024 Earnings Call
Positive tone PEDMARK U.S. commercial launch challenges Norgine ex-U.S. licensing partnership FDA safety communication on substitution
Revenue
$25.38M
▲ 1413.2% YoY
Diluted EPS
$0.41
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Fennec Pharmaceuticals Inc. Q4 FY2023 Earnings Call
Confident tone PEDMARK US commercial launch Norgine licensing deal for Europe FDA communication on sodium thiosulfate substitutions
Revenue
$9.73M*
Gross margin
93.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Fennec Pharmaceuticals Inc. Q3 FY2023 Earnings Call
Revenue
$6.51M
Diluted EPS
$-0.07
Gross margin
94.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-04
Fennec Pharmaceuticals Inc. Q2 FY2023 Earnings Call
Revenue
$3.33M
Diluted EPS
$-0.21
Gross margin
95.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Fennec Pharmaceuticals Inc. Q1 FY2023 Earnings Call
Revenue
$1.68M
Diluted EPS
$-0.23
Gross margin
94.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–15 of 15 earnings calls
Key facts CIK 1211583 CUSIP 31447P100 13F (30d) 107 filings 104 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)